{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:40:50Z","timestamp":1777560050191,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023674","name":"King Khalid University Deanship of Scientific Research","doi-asserted-by":"publisher","award":["RGP2\/312\/45"],"award-info":[{"award-number":["RGP2\/312\/45"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrc.2025.151382","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T23:08:11Z","timestamp":1737846491000},"page":"151382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Selective inhibition of p300 by a novel small molecule EPS496 promotes cell death in vemurafenib-resistant BRAFV600E mutated melanoma cells"],"prefix":"10.1016","volume":"750","author":[{"given":"Maha","family":"Alamodi Alghamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-4014","authenticated-orcid":false,"given":"Hemali","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.151382_bib1","article-title":"A review of epidemiology and cancer biology of malignant melanoma","volume":"13","author":"Davey","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2025.151382_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12935-023-03012-7","article-title":"Current status of skin cancers with a focus on immunology and immunotherapy","volume":"23","author":"Khayyati Kohnehshahri","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrc.2025.151382_bib3","volume":"vol. 11","author":"Conforti","year":"2021"},{"key":"10.1016\/j.bbrc.2025.151382_bib4","first-page":"13","article-title":"Advances in early detection of melanoma and the future of at-home testing","author":"Garrison","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.bbrc.2025.151382_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.965630","article-title":"Early and accurate detection of melanoma skin cancer using hybrid level set approach","volume":"13","author":"Ragab","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2025.151382_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245868","article-title":"Possible explanations for rising melanoma rates despite increased sunscreen use over the past several decades","volume":"15","author":"Lapides","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185409","article-title":"Advancements and challenges in personalized therapy for BRAF-mutant melanoma: a comprehensive review","volume":"13","author":"Shebrain","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrc.2025.151382_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5114\/ada.2019.84590","article-title":"Molecular background of skin melanoma development and progression: therapeutic implications","volume":"36","author":"Olbryt","year":"2019","journal-title":"Post\u0119py Dermatologii i Alergologii"},{"key":"10.1016\/j.bbrc.2025.151382_bib9","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S1470-2045(22)00010-9","article-title":"Nivolumab plus ipilimumab in melanoma brain metastases","volume":"23","author":"Rizzo","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.151382_bib10","first-page":"16","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis","author":"Sahin","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib11","first-page":"14","article-title":"Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study","author":"Rizzo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092607","article-title":"BRAF V600-mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge","volume":"15","author":"Florent","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib14","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN tumor suppressor network in PI3K-akt pathway control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes & cancer"},{"key":"10.1016\/j.bbrc.2025.151382_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144852","article-title":"WNT signaling in melanoma","volume":"21","author":"Gajos-Michniewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151382_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: biological insights and clinical implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bbrc.2025.151382_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102801","article-title":"Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081176","article-title":"Adaptive responses as mechanisms of resistance to BRAF inhibitors in melanoma","volume":"11","author":"Saei","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib20","doi-asserted-by":"crossref","first-page":"78174","DOI":"10.18632\/oncotarget.19836","article-title":"BRAF inhibitors: resistance and the promise of combination treatments for melanoma","volume":"8","author":"Griffin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2025.151382_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021601","article-title":"Phenotype switching and the melanoma microenvironment; impact on immunotherapy and drug resistance","volume":"24","author":"Hossain","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151382_bib22","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","article-title":"Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.bbrc.2025.151382_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","journal-title":"Support. Care Cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.bbrc.2025.151382_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1039121","article-title":"The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"9","author":"Guven","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbrc.2025.151382_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411299","article-title":"Unravelling the role of P300 and TMPRSS2 in prostate cancer: a literature review","volume":"24","author":"Gioukaki","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151382_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12032-022-01846-1","article-title":"Insilco and Invitro approaches identify novel dual PI3K\/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations","volume":"39","author":"Abohassan","year":"2022","journal-title":"Med. Oncol. (Lond.)"},{"key":"10.1016\/j.bbrc.2025.151382_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.32604\/or.2023.043139","article-title":"High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR-HER2 dual inhibitor in gastric tumors","volume":"32","author":"Shahrani","year":"2023","journal-title":"Oncology research"},{"key":"10.1016\/j.bbrc.2025.151382_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108180","article-title":"Uncovering the antidiabetic potential of heart-friendly and diuretic bioactive compounds through computer-based drug design","volume":"112","author":"Ercin","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151382_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3727\/096504021X16281573507558","article-title":"A combined chemical, computational, and in vitro approach identifies SBL-105 as novel DHODH inhibitor in acute myeloid leukemia cells","volume":"28","author":"Kamli","year":"2022","journal-title":"Oncology research"},{"key":"10.1016\/j.bbrc.2025.151382_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2022.103285","article-title":"CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS\/RAF\/MEK\/ERK and PI3K\/Akt signaling pathways","volume":"29","author":"Al Shahrani","year":"2022","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.bbrc.2025.151382_bib31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12885-018-4583-3","article-title":"Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines","volume":"18","author":"Xiao","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2025.151382_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.151382_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051115","article-title":"Resistance to molecularly targeted therapies in melanoma","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib34","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1128\/MCB.25.15.6592-6602.2005","article-title":"Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity","volume":"25","author":"Huang","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.151382_bib35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1046\/j.1471-4159.1999.02037.x","article-title":"Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons","volume":"73","author":"Matsuzaki","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbrc.2025.151382_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ars.2010.3560","article-title":"Knockdown of Akt1 promotes Akt2 upregulation and resistance to oxidative-stress-induced apoptosis through control of multiple signaling pathways","volume":"15","author":"Zhang","year":"2011","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.bbrc.2025.151382_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-020-01008-4","article-title":"Tumor and systemic immunomodulatory effects of MEK inhibition","volume":"23","author":"Dennison","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbrc.2025.151382_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030716","article-title":"Computational and preclinical analysis of 2-(4-Methyl)benzylidene-4,7-dimethyl indan-1-one (IPX-18): a novel arylidene indanone small molecule with anti-inflammatory activity via NF-\u03baB and Nrf2 signaling","volume":"11","author":"Gahtani","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrc.2025.151382_bib40","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.bbrc.2025.151382_bib41","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/MD.0000000000000157","article-title":"Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient","volume":"93","author":"Mackiewicz-Wysocka","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.bbrc.2025.151382_bib42","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2025.151382_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol. : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"10.1016\/j.bbrc.2025.151382_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib45","doi-asserted-by":"crossref","first-page":"51301","DOI":"10.18632\/oncotarget.10117","article-title":"P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer","volume":"7","author":"Ono","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2025.151382_bib46","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2025.151382_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00018-022-04132-5","article-title":"Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes","volume":"79","author":"Choi","year":"2022","journal-title":"Cell. Mol. Life Sci. : CM"},{"key":"10.1016\/j.bbrc.2025.151382_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biom13030417","article-title":"Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification","volume":"13","author":"Zeng","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.151382_bib49","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1038\/s41388-021-01834-1","article-title":"Targeting the p300\/NONO axis sensitizes melanoma cells to BRAF inhibitors","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2025.151382_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2407-14-398","article-title":"A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma","volume":"14","author":"Bhandaru","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2025.151382_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235858","article-title":"Epigenetic mechanisms underlying melanoma resistance to immune and targeted therapies","volume":"14","author":"Rubanov","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.151382_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12964-022-00989-y","article-title":"PI3K\/AKT signaling allows for MAPK\/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma","volume":"20","author":"Corrales","year":"2022","journal-title":"Cell Commun. Signal. : CCS"},{"key":"10.1016\/j.bbrc.2025.151382_bib53","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1038\/s41467-023-43519-1","article-title":"HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis","volume":"14","author":"Emmons","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2025.151382_bib54","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Spriano","year":"2020","journal-title":"Blood advances"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:06:55Z","timestamp":1740467215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"alternative-id":["S0006291X25000968"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151382","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective inhibition of p300 by a novel small molecule EPS496 promotes cell death in vemurafenib-resistant BRAFV600E mutated melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151382"}}